MedTech Dive January 18, 2024
Nick Paul Taylor

A study found the sensitivity of the device was 96%, compared with 83% for primary care physicians.

Dive Brief:

  • Dermasensor has received 510(k) clearance for a wireless, handheld device designed to detect common skin cancers.
  • The device uses artificial intelligence (AI) to analyze light scattered back from skin lesions. Cancerous and benign lesions reportedly give off different light signatures because of cellular and subcellular changes in tumors, according to Dermasensor, and the AI is trained to detect those distinct patterns.
  • Dermasensor received Food and Drug Administration clearance after a Mayo Clinic-led clinical trial found the overall sensitivity of the device for malignancy detection was 96%, compared to 83% for primary care physicians.

Dive Insight:

Most skin cancers...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
Medtronic, Tempus testing AI to find potential TAVR patients
AI Robot Scanner as Good as Rheumatologists at Assessing RA
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices
From SpaceTech to MedTech: What medical device engineering teams can learn from aerospace
Boston Scientific to buy Intera Oncology, maker of liver cancer treatment

Share This Article